Asset Details
Do you wish to reserve the book?
Editorial: Insights in experimental pharmacology and drug discovery: 2022
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Editorial: Insights in experimental pharmacology and drug discovery: 2022
Do you wish to request the book?
Editorial: Insights in experimental pharmacology and drug discovery: 2022
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Editorial: Insights in experimental pharmacology and drug discovery: 2022
2023
Overview
Aromatase inhibitors, which inhibit the conversion of androgens to estrogens, have had extensive use for more than 40 years to treat postmenopausal breast cancer as well as used in clinical studies for endometrial, ovarian cancers, and endometriosis. [...]showing the importance of targeting estrogen formation and metabolism in cancer treatment, sulfatase inhibitors that target the enzyme responsible for the hydrolysis of inactive estrogen-sulfates have entered clinical trials for the treatment of breast, endometrial cancers, and endometriosis, primarily demonstrating effects in breast cancer. Deficiency in BH4 leads to various symptoms in the peripheral and central nervous systems. [...]an ideal therapeutic approach would involve blocking excessive BH4 production while preventing BH4 depletion. [...]the current Research Topic included an original article that presented the role of cyclic nucleotides, specifically 3′,5′-cyclic adenosine monophosphate (cAMP) and 3′,5′-cyclic guanosine monophosphate (cGMP), in fundamental brain functions, including learning and memory.Yanai et al.demonstrated that phosphodiesterase 3 (PDE3) regulated the cellular content of cAMP and cGMP, which is in agreement with previous studies showing that long-term administration of cilostazol, a PDE3 inhibitor, improved memory performance in aging mice.
